Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals Inc

ACAD

Get informed when a big investor buys or sells

+ Follow
Market Cap$4.77B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Acadia Pharmaceuticals IncAcadia Pharmaceuticals Inc12.4-29%4.60.1
$33.71

Target Price by Analysts

21.1% upsideAcadia Pharmaceuticals Target Price DetailsTarget Price
$-10.25

Current Fair Value

136.8% downside

Overvalued by 136.8% based on the discounted cash flow analysis.

Share Statistics

Market cap$4.77 Billion
Enterprise Value$4.45 Billion
Dividend Yield$- (-)
Earnings per Share$2.32
Beta0.86
Outstanding Shares171,603,000

Return

Return on Equity29.12%ROE
Return on Assets21.83%
Return on Invested Capital6.27%

Valuation & Multiples

P/E Ratio12.37P/E Ratio
PEG68.23PEG
Price to Sales4.64Price to Sales
Price to Book Ratio3.98Price to Book Ratio
Enterprise Value to Revenue3.91
Enterprise Value to EBIT51.4
Enterprise Value to Net Income11
Total Debt to Enterprise0.02
Debt to Equity0.06Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 5, 2026
EPS Estimate
$0.06
Average shareholder expectation
Revenue Estimate
$295.83 M
Average shareholder expectation

Next Earnings Call

Expected Date
November 4, 2026
EPS Estimate
$0.21
Average shareholder expectation
Revenue Estimate
$332.29 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio1.0008▲ 31.99%
Total Calls246,100▼ 54.60%
Total Puts246,300▼ 33.27%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %99.00%▲ 2.34%
Total Invested$4.30B▲ 17.14%
Investors Holding364▲ 6.00%

ESG Score

No data

About Acadia Pharmaceuticals Inc

CEO: Uli Hacksell